HE
HEMO.LSE Hemogenyx Pharmaceuticals PLC
- Market cap
- GBX 44.1M
- P/E
- -
- P/B
- 9.63x
- ROE
- -605.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is HEMO.LSE undervalued?
Graham numberThe Graham number of Hemogenyx Pharmaceuticals PLC cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hemogenyx Pharmaceuticals PLC fundamental analysis
No fundamental analysis for Hemogenyx Pharmaceuticals PLC yet.
Hemogenyx Pharmaceuticals PLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hemogenyx Pharmaceuticals PLC
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer in the United Kingdom and the United States. The company's lead product candidate is the HG-CT-1 therapy for the treatment of relapsed or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat viral infections derived and for certain cancer and neurological conditions; and CDX bi-specif…
Full company profileHemogenyx Pharmaceuticals PLC financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hemogenyx Pharmaceuticals PLC annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | 0.00 | -100K | -348K | -422K | -351K | -284K | -2.60M | -646K | -639K | -589K | -985K |
| Operating Income | -520K | -821K | -1.62M | -1.68M | -2.15M | -2.70M | 4.00M | -5.56M | -5.73M | -4.66M | -29.9M |
| EBITDA | -447K | -837K | -1.63M | -1.36M | -1.96M | -2.39M | -3.42M | -5.73M | -4.71M | -4.07M | -29.3M |
| Net Income | -520K | -2.36M | -1.48M | -1.45M | -2.08M | -5.10M | -3.98M | -6.69M | -5.62M | -9.76M | -26.2M |
| EPS | -0.58 | -3.63 | -1.64 | -1.61 | -2.01 | -2.64 | -1.62 | -2.37 | -1.70 | -2.20 | -4.07 |
| Balance Sheet | |||||||||||
| Total Assets | 1.05M | 2.40M | 2.30M | 1.05M | 2.66M | 8.52M | 7.09M | 6.11M | 4.21M | 4.18M | 6.87M |
| Total Liabilities | 144K | 264K | 1.34M | 1.40M | 1.79M | 353K | 3.85M | 3.32M | 3.36M | 3.03M | 2.60M |
| Shareholders' Equity | 904K | 2.13M | 959K | -347K | 891K | 8.19M | 3.28M | 2.82M | 898K | 1.20M | 4.33M |
| Cash & Short-term Investments | 1.05M | 1.88M | 1.76M | 499K | 1.81M | 6.84M | 2.53M | 1.25M | 159K | 1.59M | 4.58M |
| Total Debt | 301K | - | 1.17M | 1.26M | 1.63M | 10.2K | 3.42M | 2.95M | 2.62M | 2.00M | 1.85M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -278K | -453K | -1.35M | -1.20M | -1.80M | -2.63M | -2.91M | -6.11M | -4.12M | -3.45M | -6.62M |
| Capital Expenditure | 188.79 | 64.3K | 24.6K | 11.9K | 173K | 818K | 429K | 117K | 13.3K | 3.92K | 0.00 |
| Free Cash Flow | -278K | -517K | -1.38M | -1.21M | -1.97M | -3.45M | -3.34M | -6.22M | -4.13M | -3.45M | -6.62M |
| Ratios | |||||||||||
| ROE | -57.5% | -110.8% | -154.0% | - | -233.7% | -62.2% | -121.5% | -237.4% | -626.1% | -816.5% | -605.8% |
| ROA | -49.6% | -98.6% | -64.3% | -138.4% | -78.1% | -59.8% | -56.1% | -109.6% | -133.4% | -233.7% | -381.5% |
| Debt to Equity | 0.33x | - | 1.22x | - | 1.83x | 0.00x | 1.05x | 1.05x | 2.92x | 1.68x | 0.43x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Hemogenyx Pharmaceuticals PLC dividends
Hemogenyx Pharmaceuticals PLC has not paid dividends in the last 9 fiscal years.
Last stock split: 1:400 on Dec 13, 2024.
Who owns Hemogenyx Pharmaceuticals PLC
- Insiders 29.02%
- Institutions 0.40%
- Public & others 70.58%
- Shares outstanding 6.90M
- Free float 5.27M
Hemogenyx Pharmaceuticals PLC company profile
- Company name
- Hemogenyx Pharmaceuticals PLC
- Ticker
- HEMO.LSE
- ISIN
- GB00BYX3WZ24
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 16
- Fiscal year end
- December
- Address
- 6 Heddon Street, London, United Kingdom, W1B 4BT
- Phone
- 44 79 0917 7311
- Website
- hemogenyx.com
About Hemogenyx Pharmaceuticals PLC
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer in the United Kingdom and the United States. The company's lead product candidate is the HG-CT-1 therapy for the treatment of relapsed or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat viral infections derived and for certain cancer and neurological conditions; and CDX bi-specific antibody which eliminates hematopoietic stem cells/hematopoietic progenitors in a patient using bi-specific antibodies; and therapies for the improvement of bone marrow and blood stem cell transplant procedures. The company also treats for solid and rare cancers; and immune system and autoimmune diseases. Hemogenyx Pharmaceuticals Plc was incorporated in 2013 and is headquartered in London, the United Kingdom.
Hemogenyx Pharmaceuticals PLC management
3- Dr. Vladislav Sandler Ph.D.Co-Founder, CEO & Director · born 1965
- Ms. Alexis M. Sandler J.D.Co-Founder & Independent Non-Executive Director · born 1976
- Dr. Koen Van Besien M.D., Ph.D.Clinical Advisor & Medical Director